OC
PTX

Oppenheimer & Co’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Oppenheimer & Co’s Portfolio PTX Stock Details PTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,350
Closed -$8K – 1390
2016
Q3 		$8K Sell
1,350
-120
-8% -$740 ﹤0.01% 1267
2016
Q2 		$7K Sell
1,470
-300
-17% -$1.96K ﹤0.01% 1219
2016
Q1 		$18K Sell
1,770
-450
-20% -$8.94K ﹤0.01% 1234
2015
Q4 		$66K Sell
2,220
-165
-7% -$4.99K ﹤0.01% 1233
2015
Q3 		$76K Buy
2,385
+350
+17% +$16.7K ﹤0.01% 1286
2015
Q2 		$121K Buy
2,035
+1,025
+101% +$72.3K ﹤0.01% 1389
2015
Q1 		$108K Buy
+1,010
New +$96.3K ﹤0.01% 1404

Other funds holding PTX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Oppenheimer & Co's PTX Position: Q4 2016 in Review

Oppenheimer & Co sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q4 2016, closing a stake of 1,350 shares — an estimated $8K sold.

Oppenheimer & Co first reported a position in PTX in Q1 2015 and held it in 7 quarters. The position peaked at $121K in Q2 2015. 34 funds tracked by Wall St. Rank hold PTX as of Q4 2016.

  • Oppenheimer & Co reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q4 2016 after selling out during the quarter.
  • Oppenheimer & Co sold 1,350 Pernix Therapeutics Holdings, Inc. shares in Q4 2016, an estimated $8K.
  • Oppenheimer & Co first reported a position in Pernix Therapeutics Holdings, Inc. in Q1 2015 and held it in 7 quarters.
  • Oppenheimer & Co's Pernix Therapeutics Holdings, Inc. position peaked at $121K in Q2 2015.
  • 34 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q4 2016.

Based on Oppenheimer & Co's 13F filing for Q4 2016, filed 2 Feb 2017.